MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
*Architects: Gastroenterology_Gastrointestinal (to include Liver, Pancreas & metabolic dysfunction-associated steatotic liver disease (MASLD), Gout, MASH (Metabolic dysfunction-associated steatohepatitis), formerly, NASH (Non-Alcoholic SteatoHepatitis)Non-Alcoholic SteatoHepatitis (NASH)
Enanta Pharmaceuticals, Inc (NASDAQ: ENTA)*
Finance & Acquisitions: Enanta
Parents
Enanta Pharmaceuticals, Inc (NASDAQ: ENTA)*
Children
2013: Gross IPO Proceeds (2013):Enanta Pharmaceuticals-ENTA=$64.4 million
2014: Enanta to get $40M upon AbbVie's filing for hepatitis C drug (2014)
Jumps
*Key People: Enanta
Organization & Developments: Enanta